Annemieke van der Padt-Pruijsten1,2, Maria B L Leys3, Esther Oomen-de Hoop4, Agnes van der Heide5, Carin C D van der Rijt4. 1. Department of Internal Medicine, Maasstad Hospital, Rotterdam, the Netherlands. PruijstenA@maasstadziekenhuis.nl. 2. Department Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. PruijstenA@maasstadziekenhuis.nl. 3. Department of Internal Medicine, Maasstad Hospital, Rotterdam, the Netherlands. 4. Department Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. 5. Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Abstract
PURPOSE: Adequate integration of palliative care in oncological care can improve the quality of life in patients with advanced cancer. Whether such integration affects the use of diagnostic procedures and medical interventions has not been studied extensively. We investigated the effect of the implementation of a standardized palliative care pathway in a hospital on the use of diagnostic procedures, anticancer treatment, and other medical interventions in patients with incurable cancer at the end of their life. METHODS: In a pre- and post-intervention study, data were collected concerning adult patients with cancer who died between February 2014 and February 2015 (pre-PCP period) or between November 2015 and November 2016 (post-PCP period). We collected information on diagnostic procedures, anticancer treatments, and other medical interventions during the last 3 months of life. RESULTS: We included 424 patients in the pre-PCP period and 426 in the post-PCP period. No differences in percentage of laboratory tests (85% vs 85%, p = 0.795) and radiological procedures (85% vs 82%, p = 0.246) were found between both groups. The percentage of patients who received anticancer treatment or other medical interventions was lower in the post-PCP period (40% vs 22%, p < 0.001; and 42% vs 29%, p < 0.001, respectively). CONCLUSIONS: Implementation of a PCP resulted in fewer medical interventions, including anticancer treatments, in the last 3 months of life. Implementation of the PCP may have created awareness among physicians of patients' impending death, thereby supporting caregivers and patients to make appropriate decisions about medical treatment at the end of life. TRIAL REGISTRATION NUMBER: Netherlands Trial Register; clinical trial number: NL 4400 (NTR4597); date registrated: 2014-04-27.
PURPOSE: Adequate integration of palliative care in oncological care can improve the quality of life in patients with advanced cancer. Whether such integration affects the use of diagnostic procedures and medical interventions has not been studied extensively. We investigated the effect of the implementation of a standardized palliative care pathway in a hospital on the use of diagnostic procedures, anticancer treatment, and other medical interventions in patients with incurable cancer at the end of their life. METHODS: In a pre- and post-intervention study, data were collected concerning adult patients with cancer who died between February 2014 and February 2015 (pre-PCP period) or between November 2015 and November 2016 (post-PCP period). We collected information on diagnostic procedures, anticancer treatments, and other medical interventions during the last 3 months of life. RESULTS: We included 424 patients in the pre-PCP period and 426 in the post-PCP period. No differences in percentage of laboratory tests (85% vs 85%, p = 0.795) and radiological procedures (85% vs 82%, p = 0.246) were found between both groups. The percentage of patients who received anticancer treatment or other medical interventions was lower in the post-PCP period (40% vs 22%, p < 0.001; and 42% vs 29%, p < 0.001, respectively). CONCLUSIONS: Implementation of a PCP resulted in fewer medical interventions, including anticancer treatments, in the last 3 months of life. Implementation of the PCP may have created awareness among physicians of patients' impending death, thereby supporting caregivers and patients to make appropriate decisions about medical treatment at the end of life. TRIAL REGISTRATION NUMBER: Netherlands Trial Register; clinical trial number: NL 4400 (NTR4597); date registrated: 2014-04-27.
Authors: Annemieke van der Padt-Pruijsten; Maria B L Leys; Esther Oomen-de Hoop; Agnes van der Heide; Carin C D van der Rijt Journal: J Pain Symptom Manage Date: 2021-02-07 Impact factor: 3.612
Authors: Craig C Earle; Mary Beth Landrum; Jeffrey M Souza; Bridget A Neville; Jane C Weeks; John Z Ayanian Journal: J Clin Oncol Date: 2008-08-10 Impact factor: 44.544
Authors: Joanna Paladino; Luca Koritsanszky; Brandon J Neal; Joshua R Lakin; Jane Kavanagh; Stu Lipsitz; Erik K Fromme; Justin Sanders; Evan Benjamin; Susan Block; Rachelle Bernacki Journal: J Palliat Med Date: 2020-01-03 Impact factor: 2.947
Authors: Matthew C Cheung; Craig C Earle; Jagadish Rangrej; Thi H Ho; Ning Liu; Lisa Barbera; Refik Saskin; Joan Porter; Soo Jin Seung; Nicole Mittmann Journal: Cancer Date: 2015-05-29 Impact factor: 6.860
Authors: Susan Y Wu; Lisa Singer; Lauren Boreta; Michael A Garcia; Shannon E Fogh; Steve E Braunstein Journal: BMC Palliat Care Date: 2019-03-23 Impact factor: 3.234
Authors: Manon S Boddaert; Chantal Pereira; Jeroen Adema; Kris C P Vissers; Yvette M van der Linden; Natasja J H Raijmakers; Heidi P Fransen Journal: BMJ Support Palliat Care Date: 2020-12-22 Impact factor: 4.633